109202 ⎘
Structure or type of the nucleic acid; Chemical structure; Nature of the modification linked to the nucleic acid via a carbon atom MOE, methoxyethoxy
Compounds and Methods for Reducing ATXN3 Expression
#2Cyclic Antisense Therapeutics
#3COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
#4COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER BY TARGETING THE BRCA1 PSEUDOGENE (BRCA1P1)
#5Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof
#6CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
#7ANTISENSE OLIGOMERS AGAINST MONOAMINE OXIDASE B AND USE THEREOF
#8METHODS AND COMPOSITIONS FOR MODULATING APOLIPOPROTEIN (A) EXPRESSION
#9Compounds and Methods for Reducing LRRK2 Expression
#10MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS
#11Antisense Nucleic Acids
#12RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
#13THERAPEUTIC OLIGONUCLEOTIDES
#14ANTISENSE NUCLEIC ACIDS
#15LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#16COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
#17DYSTROPHIN EXON SKIPPING OLIGONUCLEOTIDES
#18Compounds and methods for reducing LRRK2 expression
#19ANTISENSE INHIBITORS OF MIR17HG PRE-RNA AS THERAPEUTIC AGENTS IN CANCER
#20Compositions and methods for modulating apolipoprotein (a) expression
#21TREATMENT FOR TYROSINE DEGRADATION-ASSOCIATED DISORDERS
#22Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs
#23ALLELE-SELECTIVE COMPOUNDS AND METHODS FOR MODULATING HUNTINGTIN EXPRESSION
#24MODULATION OF PREKALLIKREIN (PKK) EXPRESSION
#25Antisense oligonucleotide targeting ATN1 mRNA or pre-mRNA
#26COMPOUNDS AND METHODS FOR REDUCING TAU EXPRESSION
#27CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
#28COMPOUNDS AND METHODS FOR REDUCING PLN EXPRESSION
#29MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY
#30COMPOUNDS AND METHODS FOR REDUCING ATXN3 EXPRESSION
#31METHODS AND COMPOSITIONS FOR MODULATING APOLIPOPROTEIN (A) EXPRESSION
#32COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSION
#33COMPOUNDS AND METHODS FOR MODULATING PMP22
#34Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof
#35MODULATORS OF FOXP3 EXPRESSION
#36Modulation of Dystrophia Myotonica-Protein Kinase (DMPK) Expression
#37Insulin receptor aptamer and pharmaceutical composition for treating diabetes comprising the same
#38COMPOSITIONS AND METHODS FOR SILENCING SCN9A EXPRESSION
#39COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION
#40ANTISENSE NUCLEIC ACIDS
#41Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof
#42Compounds and methods for reducing LRRK2 expression
#43COMPOSITIONS AND METHODS FOR MODULATING ATAXIN 3 EXPRESSION
#44RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA)
#45COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION
#46COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSION
#47ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF USHER SYNDROME
#48MODULATION OF TRANSTHYRETIN EXPRESSION
#49TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF
#50Modulation of prekallikrein (PKK) expression
#51ANTISENSE NUCLEIC ACIDS
#52ANTISENSE OLIGONUCLEOTIDE-BASED PROGRANULIN AUGMENTATION THERAPY IN NEURODEGENERATIVE DISEASES
#53OLIGONUCLEOTIDES FOR USE IN THE TREATMENT OF DYSTROPHIC EPIDERMOLYSIS BULLOSA
#54COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING AMYOTROPHIC LATERAL SCLEROSIS
#55METHODS AND COMPOSITIONS USING RNA INTERFERENCE AND ANTISENSE OLIGONUCLEOTIDES FOR INHIBITION OF KRAS
#56CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF
#57COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
#58Antisense oligonucleotide-based progranulin augmentation therapy in neurodegenerative diseases
#59OLIGONUCLEOTIDE MEDIATED NO-GO DECAY
#60GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof
#61ANTISENSE NUCLEIC ACIDS
#62Compounds and Methods for Modulation of Transcript Processing
#63ANTISENSE NUCLEIC ACIDS
#64LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#65Antisense nucleic acids
#66ANTISENSE NUCLEIC ACIDS
#67Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof
#68COMPOSITIONS AND METHODS
#69Therapeutic oligonucleotides
#70Compositions and methods for modulating apolipoprotein (a) expression
#71ANTISENSE OLIGONUCLEOTIDES FOR RNA EDITING
#72Antisense oligonucleotide compositions
#73Interfering RNA molecules
#74CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
#75Oligonucleotide therapy for Wilson disease
#76COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION
#77Methods and compositions for modulating apolipoprotein (a) expression
#78Oligomeric compounds comprising bicyclic nucleotides and uses thereof
#79Modulation of Dystrophia Myotonica-Protein Kinase (DMPK) Expression
#80RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (SINA)
#81Compositions and methods for modulating Ataxin 3 expression
#82TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF
#83METHODS AND COMPOSITIONS FOR MODULATING APOLIPOPROTEIN (A) EXPRESSION
#84Methods and compositions using RNA interference and antisense oligonucleotides for inhibition of KRAS
#85COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION
#86LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#87Compounds and methods for reducing Tau expression
#88COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSION
#89Modulators of FOXP3 expression
#90Antisense nucleic acids
#91Antisense nucleic acids
#92LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#93Antisense nucleic acids
#94Antisense nucleic acids
#95Compositions and methods for modulation of IKBKAP splicing
#96Interfering RNA molecules
#97Conjugated antisense compounds and their use
#98COMPOUNDS AND METHODS FOR MODULATION OF TRANSCRIPT PROCESSING
#99Antisense nucleic acids
#100CAMK2D antisense oligonucleotides and uses thereof
#101Compounds and methods for reducing ATXN3 expression
#102MOLECULAR RE-ENGINEERING OF EXCITATION-INHIBITION BALANCE IN MEMORY CIRCUITS
#103Modulation of prekallikrein (PKK) expression
#104Antisense nucleic acids
#105COMPOUNDS AND METHODS FOR REDUCING TAU EXPRESSION
#106Antisense nucleic acids
#107Antisense nucleic acids
#108OLIGOMERIC COMPOUNDS COMPRISING BICYCLIC NUCLEOTIDES AND USES THEREOF
#109GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof
#110COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF CANCER USING SLNCR ISOFORMS
#111Modulation of angiopoietin-like 3 expression
#112Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#113COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION
#114TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF
#115Interfering RNA molecules
#116Methods for modulating Ataxin 2 expression
#117Compositions and methods for modulating angiopoietin-like 3 expression
#118Compositions and methods for modulation of IKBKAP splicing
#119MicroRNA Compounds and Methods for Modulating MIR-21 Activity
#120Compositions and their uses directed to huntingtin
#121COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION
#122COMPOUNDS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION FOR IMPROVING A DIABETIC PROFILE
#123MicroRNA Compounds and Methods for Modulating MIR-21 Activity
#124Interfering RNA molecules
#125COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING
#126Compositions and methods for modulating apolipoprotein (a) expression
#127Compositions and methods for modulating apolipoprotein C-III expression
#128MODULATION OF TRANSTHYRETIN EXPRESSION
#129Compositions and their uses directed to huntingtin
#130MODULATORS OF KRAS EXPRESSION
#131Compositions and methods for modulating Ataxin 3 expression
#132Methods and compositions for modulating apolipoprotein (a) expression
#133Oligomeric compounds comprising bicyclic nucleotides and uses thereof
#134Methods and compositions for modlating apolipoprotein (A) expression
#135Modified TGF-beta oligonucleotides
#136Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
#137Modulation of TMPRSS6 expression
#138Interfering RNA molecules
#139THERAPEUTIC OLIGONUCLEOTIDES
#140COMPOUNDS AND METHODS FOR MODULATING TARGET NUCLEAR AND SUB-NUCLEAR NUCLEIC ACID MOLECULES IN CELLS AND ANIMALS
#141Micromirs
#142MODULATION OF TRANSTHYRETIN EXPRESSION
#143MODULATION OF TRANSTHYRETIN EXPRESSION
#144MODULATION OF TRANSTHYRETIN EXPRESSION
#145MODULATION OF TRANSTHYRETIN EXPRESSION
#146MODULATION OF TRANSTHYRETIN EXPRESSION
#147MODULATION OF TRANSTHYRETIN EXPRESSION
#148MODULATION OF TRANSTHYRETIN EXPRESSION
#149MODULATION OF TRANSTHYRETIN EXPRESSION
#150MODULATION OF TRANSTHYRETIN EXPRESSION
#151MODULATION OF TRANSTHYRETIN EXPRESSION
#152MODULATION OF DYSTROPHIA MYOTONICA-PROTEIN KINASE (DMPK) EXPRESSION
#153UNA oligomers and compositions for treating amyloidosis
#154Modulation of nuclear-retained RNA
#155ANTISENSE COMPOUNDS TARGETING GENES ASSOCIATED WITH FIBRONECTIN
#156Antisense compounds targeting genes associated with cystic fibrosis
#157Compounds and methods for reducing Tau expression
#158Compounds and methods for modulating TMPRSS6 expression
#159RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA)
#160Compositions for modulating Tau expression
#161EFFECTS OF APOLIPOPROTEIN B INHIBITION ON GENE EXPRESSION PROFILES IN ANIMALS
#162MODIFIED TGF-BETA2 OLIGONUCLEOTIDES
#163Modulation of huntingtin expression
#164Modulation of alpha synuclein expression
#165Compositions and methods for modulating Tau expression
#166Compositions and methods for modulating TTR expression
#167Modulation of UBE3A-ATS expression
#168Conjugated antisense compounds and their use
#169Antisense nucleic acids
#170Modulation of prekallikrein (PKK) expression
#171Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#172Interfering RNA molecules
#173RAS exon 2 skipping for cancer treatment
#174TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF
#175Antisense compounds targeting apolipoprotein E receptor 2
#176Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
#177Modulation of prekallikrein (PKK) expression
#178Molecular re-engineering of excitation-inhibition balance in memory circuits
#179MicroRNA compounds and methods for modulating miR-21 activity
#180Antisense compounds targeting genes associated with cystic fibrosis
#181Compounds and methods for modulating target nuclear and sub-nuclear nucleic acid molecules in cells and animals
#182Compounds and methods for modulating target nuclear and sub-nuclear nucleic acid molecules in cells and animals
#183Dengue virus-specific siRNA, double helix oligo-RNA structure comprising siRNA, and composition for suppressing proliferation of dengue virus comprising RNA structure
#184Methods and compositions for modulating apolipoprotein (a) expression
#185DOUBLE STRAND COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENE MODULATION
#186MODULATION OF RENIN-ANGIOTENSIN SYSTEM (RAS) RELATED DISEASES BY ANGIOTENSINOGEN
#187Oligomeric compounds comprising bicyclic nucleosides and uses thereof
#188Oligomeric compounds comprising bicyclic nucleotides and uses thereof
#189Antisense modulation of superoxide dismutase 1, soluble expression
#190Antisense nucleic acids
#191Antisense modulation of GCCR expression
#192Antisense modulation of GCGR expression
#193Oligonucleotides for modulation of target RNA activity
#194Compounds and methods for modulating interaction between proteins and target nucleic acids
#195Antisense nucleic acids
#196RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA)
#197Antisense modulation of GCGR expression
#198MODULATION OF GLUCOSE-6-PHOSPHATASE TRANSLOCASE EXPRESSION
#199Modulation of growth hormone receptor expression and insulin-like growth factor expression
#200MODULATION OF CETP EXPRESSION
#201DOUBLE STRAND COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENE MODULATION
#202Modulation of Hepatitis B virus (HBV) expression
#203Modulation of forkhead box O1A expression
#204TRPM-2 antisense therapy
#205COMPOSITIONS AND THEIR USES DIRECTED TO IL-4R ALPHA
#206MODULATION OF APOLIPOPROTEIN(A) EXPRESSION
#207Targeting microRNAs for the treatment of liver cancer
#208Modulation of glucagon receptor expression
#209Proinflammatory nucleic acids
#210Antisense modulation of PTP1B expression
#211Modulating Gene Expression With agRNA and Gapmers Targeting Antisense Transcripts
#212Method of inhibiting miR-33 using a modified oligonucleotide
#213Modulation of eIF4E expression
#214Modulation of signal transducer and activator of transcription 3 (STAT3)expression
#215MODULATION OF TTC39 EXPRESSION TO INCREASE HDL
#216Modulation of huntingtin expression
#217Methods for slowing familial ALS disease progression
#218MODULATION OF FACTOR 7 EXPRESSION
#219COMPOSITIONS AND METHODS FOR THE MODULATION OF JNK PROTEINS
#220Antisense oligonucleotide modulation of STAT3 expression
#221RNAi probes targeting cancer-related proteins
#222MODULATION OF SGLT-2 EXPRESSION
#223Compositions and methods for modulation of SMN2 splicing in a subject
#224Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#225MODULATION OF EIF4E-BP2
#226ANTISENSE OLIGONUCLEOTIDE MODULATION OF RAF GENE EXPRESSION
#227MODULATION OF TRANSTHYRETIN EXPRESSION
#228Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#229Modulation of STAT 6 expression
#230COMPOSITIONS AND THEIR USES DIRECTED TO HEPCIDIN
#231ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
#232Oligomeric compounds and compositions for the use in modulation of target nucleic acids
#233METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES
#234Modified oligonucleotide and its preparation and application
#235METHODS OF MODULATING AN IMMUNE RESPONSE TO A VIRAL INFECTION
#236Antisense modulation of C-reactive protein expression
#237Antisense modulation of PTP1B expression
#238Treatment of neurological disorders by dsRNA administration
#239miR-33 INHIBITORS AND USES THEREOF
#240Method for inhibiting the activity of mir-155
#241Short interfering ribonucleic acid (siRNA) for oral administration
#242Short interfering ribonucleic acid (siRNA) for oral administration
#243Antisense modulation of superoxide dismutase 1, soluble expression
#244Short interfering ribonucleic acid (siRNA) for oral administration
#245ANTISENSE MODULATION OF CHOLESTERYL ESTER TRANSFER PROTEIN EXPRESSION
#246TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF
#247Compositions and their uses directed to huntingtin
#2482'-F MODIFIED RNA INTERFERENCE AGENTS
#249Targeting MicroRNAs For The Treatment Of Liver Cancer
#250Nuclease resistant double-stranded ribonucleic acid
#251Modulation of C-reactive protein expression
#252Oligomeric compounds and compositions for use in modulation of small non-coding RNAS
#253ANTISENSE MODULATION OF STEAROYL-COA DESATURASE EXPRESSION
#254ENHANCED ANTISENSE OLIGONUCLEOTIDES
#255Modulation of HIF1α and HIF2α expression
#256METHODS FOR MODULATING EXPRESSION OF CREB
#257MODULATION OF TRANSFORMING GROWTH FACTOR-BETA 1 EXPRESSION
#258Conjugates For Use In Hepatocyte Free Uptake Assays
#259Antisense Modulation Of Amyloid Beta Protein Expression
#260Modulation of glucose-6-phosphatase translocase expression
#261Modulation of CD40 expression
#262Bispecific oligonucleotide for the treatment of CNS malignancies
#263Modulation of SMRT expression
#264NON-NATURAL RIBONUCLEOTIDES, AND METHODS OF USE THEREOF
#265Methods for modulating expression of RBP4
#266Interfering RNA molecules
#267Antisense modulation of C-reactive protein expression
#268Compositions and their uses directed to PTPRU
#269Compositions and their uses directed to gemin genes
#270Antisense formulation
#271ANTISENSE MODULATION OF BCL2-ASSOCIATED X PROTEIN EXPRESSION
#272MODULATION OF FACTOR 9 EXPRESSION
#273Method for reducing scarring during wound healing using antisense compounds directed to CTGF
#274Antisense oligonucleotide modulation of STAT3 expression
#275DOUBLE STRAND COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENE MODULATION
#276Modulation of apolipoprotein (a) expression
#277Chimeric oligomeric compounds for modulation of splicing
#278TRPM-2 antisense therapy
#279RNAi probes targeting cancer-related proteins
#280Antisense oligonucleotides targeted to the coding region of thymidylate synthase and uses thereof
#281Antidotes to antisense compounds
#282EFFECTS OF APOLIPOPROTEIN B INHIBITION ON GENE EXPRESSION PROFILES IN ANIMALS
#283Pharmaceutical compositions for treatment of HCV patients that are poor-responders to interferon
#284Modulation of SGLT2 expression
#285MODULATION OF HIF1 BETA EXPRESSION
#286Modulation of forkhead box O1A expression
#287Modulation of stat5 expression
#288Modulation of factor 7 expression
#289MicromiRs
#290Administering antisense oligonucleotides complementary to human apolipoprotein B
#291Antisense modulation of fibroblast growth factor receptor 4 expression
#292Combination treatment for the treatment of hepatitis C virus infection
#293Modulation of apolipoprotein (A) expression
#294Targeting microRNAs for the treatment of liver cancer
#295Method for inhibiting the activity of mir-155
#296Oligomeric compounds and compositions for use in modulation of pri-miRNAs
#297Antisense modulation of kinesin-like 1 expression
#298MODULATION OF GLUCAGON RECEPTOR EXPRESSION
#299MODULATION OF GLUCOCORTICOID RECEPTOR EXPRESSION
#300Compositions and methods for modulation of SMN2 splicing